title: Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study.
abstract: OBJECTIVE
  To ascertain the frequency and identify predictors of self-reported hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes.
  
  
  METHODS
  A random sample of 267 people with insulin-treated diabetes were recruited from a population-based diabetes register in Tayside, Scotland. Each subject prospectively recorded the number of mild and severe hypoglycaemic episodes experienced over a 1-month period. Ordinal logistic regression was performed to identify potential predictors of hypoglycaemia.
  
  
  RESULTS
  Five hundred and seventy-two hypoglycaemic events were reported by 155 patients. The participants with Type 1 diabetes had a total of 336 hypoglycaemic events with a rate of 42.89 events per patient per year. Of these, nine were severe hypoglycaemic events, with a rate of 1.15 events per patient per year. Participants with insulin-treated Type 2 diabetes experienced a total of 236 hypoglycaemic events with a rate of 16.37 events per patient per year. Of these, five were severe hypoglycaemic events, which would be equivalent to 0.35 events per patient per year. Predictors of hypoglycaemia in Type 1 diabetes were a history of previous hypoglycaemia (P = 0.006) and co-prescribing of any oral drug (P = 0.048). In patients with insulin-treated Type 2 diabetes, a history of previous hypoglycaemia (P < 0.0001) and duration of insulin treatment (P = 0.014) were significant predictors.
  
  
  CONCLUSIONS
  The incidence of self-reported severe hypoglycaemia in insulin-treated Type 2 diabetes is lower than in Type 1 diabetes but does occur more often than previously reported and with sufficient frequency to cause significant morbidity. Duration of insulin treatment is a key predictor of hypoglycaemia in insulin-treated Type 2 diabetes.
authors.affiliation: Medicines Monitoring Unit (MEMO), Department of Clinical Pharmacology, University of Dundee, Dundee, UK. Louised@memo.dundee.ac.uk
authors.forename: L A
authors.initials: LA
authors.lastname: Donnelly
authors.forename: A D
authors.initials: AD
authors.lastname: Morris
authors.forename: B M
authors.initials: BM
authors.lastname: Frier
authors.forename: J D
authors.initials: JD
authors.lastname: Ellis
authors.forename: P T
authors.initials: PT
authors.lastname: Donnan
authors.forename: R
authors.initials: R
authors.lastname: Durrant
authors.forename: M M
authors.initials: MM
authors.lastname: Band
authors.forename: G
authors.initials: G
authors.lastname: Reekie
authors.forename: G P
authors.initials: GP
authors.lastname: Leese
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000453:epidemiology* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012606:Scotland / Q000453:epidemiology; D013997:Time Factors
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin